Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-09-01

Clinical Trial Update: BAX 326 Pediatric Study [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for BAX 326 in pediatric patients completed phases 2 and 3 with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BAX 326 (recombinant factor IX)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Hemophilia B | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2016-09-01